SADEL project aims at developing the first generation of non-parenteral biotherapeutics tackling disease targets in digestive track by using innovative high-affinity protein scaffolds.
SADEL consortium is assembled as a virtual biopharmaceutical company with SMEs, academics, clinicians and pharma industry with all cutting-edge skills: production (including GMP), analytics, formulation, preclinical and clinical development, up to licensing.
For further information about Inflammatory Bowel Disease (IBD), please visit the ECCO Website.
Development and production of new, high- affinity protein scaffolds for therapeutic use, to replace standard antibodies treatments.
Sadel consortium is composed of nine partners from six different European countries, giving birth to an unique mix of know-how and expertise.
A VIRTUAL COMPANY
SADEL consortium assembles a virtual biopharmaceutical company, with SMEs, academics and pharma, covering all skills from research up to licensing.
SADEL project covers a sixty months’ period. Final results are thus expected to be delivered in December 2017.
The research carried out by SADEL is funded by the European Community’s 7th Framework Program, specific programme ‘Cooperation’, health priority..
The aim is to solve unmet patient needs by providing affordable, safe and efficient products in a format raising comfort and compliance to treatment..